Clinical trials recruiting in Baden, Switzerland

Phase breakdown

Conditions recruiting in Baden, Switzerland

Recruiting trials in Baden, Switzerland

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
  NCT06790693 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
  NCT06284317 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
  NCT06452277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
  NCT07203053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
  NCT02102165 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
  NCT07140172 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• DESTINY Breast Respond HER2-(Ultra)Low Europe
  NCT05945732 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06401980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• Early Detection and IntervenTion in Heart Failure
  NCT07731490 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female)
• Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism
  NCT07143539 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT06217822 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer
  NCT04289935 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• LUCINAE Registry: Thoracic Cancers During Pregnancy
  NCT07699861 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
  NCT06216301 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07149649 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Natural Course of Initially Metabolic Healthy Obese Individuals (Healthy Obesity)?
  NCT06799897 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: All (male and female)
• Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
  NCT05718323 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
  NCT07158489 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Pacing Advancements With Cost and Experience VALuation for Unified Patient-Led Clinical Evidence - the PACEVALUE Study
  NCT07276139 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
  NCT07617610 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
  NCT07020065 · Phase: Phase 2 · Ages: 70 Years and older · Sex: All (male and female)
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  NCT07100080 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
  NCT06890598 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)
  NCT07365423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• The SwissPrEPared Study
  NCT03893188 · Phase: Not specified · Ages: 16 Years to 120 Years · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
  NCT06801899 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
  NCT03819101 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male

Common questions

How many clinical trials are recruiting in Baden, Switzerland?

32 recruiting trials have at least one study site in Baden, Switzerland.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.